RSS Feeds
Aseptic Meningitis and Intravenous Immunoglobulin Therapy
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
TO THE EDITOR:
Sekul and colleagues [1] described the association between aseptic meningitis and high-dose intravenous immunoglobulin and reported that 11% (6 of 54) of their patients developed aseptic meningitis after receiving intravenous immunoglobulin. However, they did not mention the specific immunoglobulin product or products they used, although they asserted that a change in the “commercial lot or product, for unknown reasons, was effective in preventing the recurrence of aseptic meningitis”.
Considering the high incidence of aseptic meningitis reported by these authors and the fact that different intravenous immunoglobulin products vary in the type and amount of the vehicle and in their immunoglobulin contents, it would be useful if the authors provided readers with the brand name of the product or products used in their patients.
The Editors welcome submissions for possible publication in the Letters section. Authors of letters should:
•Include no more than 300 words of text, three authors, and five references
•Type with double-spacing
•Send three copies of the letter, an authors' form signed by all authors, and a cover letter describing any conflicts of interest related to the contents of the letter.
Letters commenting on an Annals article will be considered if they are received within 6 weeks of the time the article was published. Only some of the letters received can be published. Published letters are edited and may be shortened; tables and figures are included only selectively. Authors will be notified that the letter has been received. If the letter is selected for publication, the author will be notified about 3 weeks before the publication date. Unpublished letters cannot be returned.
Annals welcomes electronically submitted letters.
- Copyright ©2004 by the American College of Physicians
